GENB insider transaction filings
Generate Biomedicines, Inc. — 16 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-03-06. Screen GENB transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-03-06 | 4 | Nally Michael — Chief Executive Officer, Director | Purchase (P): 20,000 @ $12 | EDGAR |
| 2026-03-02 | 4 | Grous Beth — Chief People Officer | Purchase (P): 300 @ $16 · Grant/award (A): 114,020 (derivative) @ $0 | EDGAR |
| 2026-03-02 | 4 | Lee Laurie Anne — Chief Medical Officer | Grant/award (A): 42,230 (derivative) @ $0 | EDGAR |
| 2026-03-02 | 4 | Silvers Jason — President & CFO | Purchase (P): 500 @ $16 · Purchase (P): 500 @ $16 · Purchase (P): 1,000 @ $16 · Grant/award (A): 295,608 (derivative) @ $0 · Grant/award (A): 274,493 (derivative) @ $0 | EDGAR |
| 2026-03-02 | 4 | Grigoryan Gevorg — Chief Technology Officer | Grant/award (A): 295,608 (derivative) @ $0 · Grant/award (A): 196,368 (derivative) @ $0 | EDGAR |
| 2026-03-02 | 4 | Parker Paul Gray — Director | Grant/award (A): 29,561 (derivative) @ $0 | EDGAR |
| 2026-03-02 | 4 | Nally Michael — Chief Executive Officer, Director | Conversion (C): 658,327 · Grant/award (A): 844,595 (derivative) @ $0 · Grant/award (A): 844,595 (derivative) @ $0 · Conversion (C): 1,000,000 (derivative) @ $0 | EDGAR |
| 2026-03-02 | 4 | Vessey Rupert — Director | Grant/award (A): 29,561 (derivative) @ $0 | EDGAR |
| 2026-03-02 | 4 | Mendillo Jane L — Director | Purchase (P): 1,500 @ $16 · Grant/award (A): 29,561 (derivative) @ $0 | EDGAR |
| 2026-03-02 | 4 | ARNOLD FRANCES — Director | Grant/award (A): 29,561 (derivative) @ $0 | EDGAR |
| 2026-03-02 | 4 | Martin Sean — Chief Legal Officer & GC | Grant/award (A): 190,034 (derivative) @ $0 | EDGAR |
| 2026-03-02 | 4 | Bancel Stephane — Director | Conversion (C): 724,160 · Grant/award (A): 29,561 (derivative) @ $0 · Conversion (C): 1,100,000 (derivative) @ $0 | EDGAR |
| 2026-03-02 | 4 | Simonian Nancy A — Director | Grant/award (A): 29,561 (derivative) @ $0 | EDGAR |
| 2026-03-02 | 4 | Fanucci Marsha — Director | Grant/award (A): 29,561 (derivative) @ $0 | EDGAR |
| 2026-03-02 | 4 | AFEYAN NOUBAR — Director, 10% owner Flagship Pioneering, LLC — 10% owner Flagship VentureLabs VI Manager LLC — 10% owner Flagship Pioneering Fund VI General Partner LLC — 10% owner Flagship Pioneering Fund VII General Partner LLC — 10% owner Nutritional Health LTP Fund General Partner LLC — 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC — 10% owner FPN General Partner LLC — 10% owner | Conversion (C): 12,723,940 · Conversion (C): 13,702,224 · Conversion (C): 987,491 · Conversion (C): 2,777,752 · Conversion (C): 2,777,752 · Purchase (P): 1,562,500 @ $16 · +13 more | EDGAR |
| 2026-03-02 | 4 | AFEYAN NOUBAR — Director, 10% owner Flagship VentureLabs VI LLC — 10% owner Flagship Pioneering Fund VI, L.P. — 10% owner Flagship Pioneering Fund VII, L.P. — 10% owner Nutritional Health LTP Fund, L.P. — 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. — 10% owner FPN II, L.P. — 10% owner | Conversion (C): 12,723,940 · Conversion (C): 13,702,224 · Conversion (C): 987,491 · Conversion (C): 2,777,752 · Conversion (C): 2,777,752 · Purchase (P): 1,562,500 @ $16 · +13 more | EDGAR |
Recent 8-K events — Generate Biomedicines, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-02 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=GENB returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →